MEDA Ventures

Investment decisions are led by Managing Partners Elizabeth Cho-Fertikh (therapeutics, regulatory strategy), Tomas Philipson (health economics), and Carolyn Campbell (fund management, legal). The firm’s venture partners — practicing physicians and researchers from institutions like Mass General Brigham and Stanford — contribute to deal-specific diligence, but the Managing Partners retain decision-making authority.

According to MEDA’s website, the firm has developed a product that can underwrite coverage of a portfolio company’s clinical-trial costs, financially protecting both startups and investors from trial failures. The mechanics — whether a balance-sheet commitment, an insurance wrapper, or a third-party facility — have not been publicly detailed. It is positioned as a differentiated de-risking tool for early-stage healthcare companies.

The firm attributes deal flow to its partners’ standing as former healthcare customers, clinicians, and key opinion leaders. Its network of early-adopting medical centers is cited as the channel that attracts startups and co-investors. The firm states this network also supports business development and potential exits for portfolio companies.

MEDA Ventures operates as an asset manager structured as a venture capital group, not a single-family office. Its partners are physicians and scientists rather than a single wealth-origin family. The firm has not disclosed the identity of its limited partners.

MEDA Ventures focuses on early-stage healthcare companies, specifically seed and start-up phases, as described in its own materials. Its portfolio companies include Nested Knowledge and DynamiCare Health, both of which were at early commercial or clinical-validation stages when the relationship was disclosed.

MEDA Ventures does not publish an open submission process or portal. Contact is routed through its general email address, info@meda.vc, per the firm’s website. Given its network-driven sourcing model, warm introductions through its clinical and scientific network are likely the primary path for consideration.

No. MEDA Ventures has not publicly disclosed an AUM or total deployment figure. The firm does not appear in the standard AUM-tracking databases. The absence of public disclosure is consistent with an early-stage or tightly held vehicle.